Alle Fälle anzeigen
UPC APP 15/2025
—·EP2401365 +1 more: REENGINEERING MRNA PRIMARY STRUCTURE FOR ENHANCED PROTEIN PRODUCTION
- Verfahrensdetails
- Status—VerfahrensartVerfahrensantragKategorieAkteneinsicht (RoP262)
- Parteien
- KlägerVertreter: Christine Kanz (Hoyng Rokh Monegier); Tobias J. Hessel (Clifford Chance)Beklagte
- BioNTech SE
- BioNTech Manufacturing GmbH
- BioNTech Manufacturing Marburg GmbH
- BioNTech Innovative Manufacturing Services GmbH
- BioNTech Europe GmbH
- Pfizer Manufacturing Belgium NV
- Pfizer SAS
- Pfizer AB
- Pfizer, Inc.
Vertreter: Georg A. Rauh (Vossius & Partner) - Division
- Munich LD
- Richter
- Andras Kupecz · Judge-rapporteur
- Technology
- Biotechnology
- Sprache
- —
- Erste Entscheidung
- 10. März 2025
Entscheidungen
- 2025-03-10Application RoP262A
The Munich Local Division granted Promosome LLC's application under Rule 262A RoP for confidentiality protection of certain exhibits (VB 4a and VB 4b) in its infringement action against BioNTech and Pfizer entities.
Rechtsfragen:Confidentiality Rule 262A RoPTrade secrets - 2025-03-10Application RoP262A
Munich Local Division issued a confidentiality order under Rule 262A RoP in the infringement action by BioNTech/Pfizer entities against Promosome LLC (EP 2 401 365). The order protected specific exhibits (VB 4a and VB 4b) containing confidential licensing information, granting access only to named representatives and specified individuals from each party. The preliminary protection from a prior order was lifted to the extent superseded.
Rechtsfragen:Confidentiality protection under Rule 262A RoPAccess restrictions to confidential exhibitsLifting of preliminary confidentiality order
Dokumente
- 21772AC18D828EF187CAB78342AE12E9_en.pdf2025-03-10EN
- EDE4EED3866CB5652F6914BB07CE9EB0_en.pdf2025-03-10EN